MIDAZOLAM by Cipla is understood, but it is thought to involve potentiation of gabaergic neurotransmission resulting from binding at the benzodiazepine site of the gaba a receptor.
Drug data last refreshed 26m ago
understood, but it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA A receptor.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Clinical Trial of MK-6916 With Midazolam and Rosuvastatin in Healthy Participants (MK-6916-012)
DDI Study of ECC0509 With Metformin, Midazolam, and Caffeine
A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy Participants
A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
Worked on MIDAZOLAM at Cipla? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.